Achillion Pharmaceuticals, Inc.

Achillion Pharmaceuticals, Inc. is dedicated to discovering and developing innovative therapies for the treatment of infectious diseases and rare disorders, particularly focusing on the development of small molecule drugs. Founded in 1998 in New Haven, US, Achillion Pharmaceuticals, Inc. specializes in the development of small molecule therapeutics.

The company has undergone strategic shifts over the years, including a recent acquisition by Domain Venture Partners Ppc. It has raised a total amount of USD 1. 890 mn through its latest funding round, an IPO. The company is led by CEOs Michael Kishbauch and Milind Deshpande, who bring extensive experience in the pharmaceutical sector.

Achillion Pharmaceuticals, Inc. develops and commercializes innovative therapies targeting infectious diseases and rare disorders. The company’s core product offerings include small molecule drugs designed to address specific therapeutic areas, enhancing treatment outcomes for patients with complex conditions. Achillion’s products are marketed through established distribution networks, ensuring broad access for healthcare providers and patients across North America, Europe, and parts of Asia.

In the most recent financial year of 2018, Achillion Pharmaceuticals reported zero revenue, with an EBITDA of USD -75,397,000. The company’s revenue model is primarily B2B, focusing on sales to healthcare institutions and specialty pharmacies for the supply of its therapeutics. To support its growth strategy, Achillion Pharmaceuticals plans to enhance its product pipeline with new therapies targeting infectious diseases and rare disorders. The company aims to expand its market presence into regions like Asia-Pacific and Latin America by 2025.

The recent IPO funding will be utilized to advance clinical trials for new treatments and to strengthen operational capabilities, supporting the overall growth objectives of the company.